 Corbus Pharmaceuticals NASDAQ:CRBP was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued to investors on Monday, Zacks.com reports. According to Zacks, Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, ... 